David Innes - Northwest Biotherapeutics VP Relations
| NWBO Stock | USD 0.26 0.01 3.70% |
Insider
David Innes is VP Relations of Northwest Biotherapeutics
| Phone | 240 497-9024 |
| Web | www.nwbio.com |
Northwest Biotherapeutics Management Efficiency
The company has return on total asset (ROA) of (1.2576) % which means that it has lost $1.2576 on every $100 spent on assets. This is way below average. Northwest Biotherapeutics' management efficiency ratios could be used to measure how well Northwest Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | INSIDER Age | ||
| Geert Esq | CEL SCI Corp | 66 | |
| Prof Schlessinger | Celldex Therapeutics | 80 | |
| Anthony MBA | Celldex Therapeutics | 63 | |
Management Performance
| Return On Asset | -1.26 |
Northwest Biotherapeutics Leadership Team
Elected by the shareholders, the Northwest Biotherapeutics' board of directors comprises two types of representatives: Northwest Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Northwest. The board's role is to monitor Northwest Biotherapeutics' management team and ensure that shareholders' interests are well served. Northwest Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Northwest Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Leslie Goldman, Sr. VP of Bus. Devel. | ||
| Linda JD, CEO, Chairperson | ||
| Alton Boynton, Founder, Chief Scientific Officer, Secretary and Director | ||
| David Innes, VP Relations | ||
| Jean Davis, Chief Officer |
Northwest Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Northwest Biotherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -1.26 | ||||
| Profit Margin | 52.10 % | ||||
| Operating Margin | (54.95) % | ||||
| Current Valuation | 1.03 B | ||||
| Shares Outstanding | 1.05 B | ||||
| Shares Owned By Insiders | 10.04 % | ||||
| Shares Owned By Institutions | 0.23 % | ||||
| Number Of Shares Shorted | 14.14 M | ||||
| Price To Earning | 58.17 X | ||||
| Price To Sales | 858.96 X |
Other Information on Investing in Northwest OTC Stock
Northwest Biotherapeutics financial ratios help investors to determine whether Northwest OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Northwest with respect to the benefits of owning Northwest Biotherapeutics security.